Suspected adverse drug reactions of the type 2 antidiabetic drug class <scp>dipeptidyl‐peptidase IV</scp> inhibitors ( <scp>DPP4i</scp> ): Can polypharmacology help explain?-Reference-Cited by-同舟云学术

Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl‐peptidase IV inhibitors ( DPP4i ): Can polypharmacology help explain?

Published:2022-12 Issue:6 Volume:10 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacology Res & Perspec

Author:

Jones Lauren¹,Jones Alan M.¹^ORCID

Affiliation:

1. Medicines Safety Research Group (MSRG), School of Pharmacy University of Birmingham Birmingham UK

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.1029

Reference78 articles.

1. World Health Organisation Diabetes 2021 10 Nov 2021; Available from:https://www.who.int/news‐room/fact‐sheets/detail/diabetes.

2. The National Institute for health and care excellence.Type 2 Diabetes in Adults: Management.201524 Nov 2021 21 Dec 2021; Available from:https://www.nice.org.uk/guidance/ng28

3. Incretin hormones: Their role in health and disease

4. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events;Ahrén B;Incretins,2009

5. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cinnamic acid and its derivatives on dipeptidyl peptidase 4: Structure-activity relationship and mechanism of inhibition;Food Bioscience;2024-12

2. The Interplay Between Molecular Architecture, Pharmacology, and Suspected Adverse Drug Reactions Associated with Non-Steroidal Androgen Antagonists in The United Kingdom;2024-07-09

3. Associations between Suspected Adverse Drug Reactions of HMG-CoA Reductase Inhibitors and Polypharmacology Using a National Registry Approach;Pharmacoepidemiology;2024-07-03

5. Suspected Adverse Drug Reactions Associated with Leukotriene Receptor Antagonists Versus First Line Asthma Medications: A National Registry-Pharmacology Approach;2024-06-13